Current Report Filing (8-k)
September 23 2021 - 6:10AM
Edgar (US Regulatory)
0001739940
false
0001739940
2021-09-20
2021-09-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September
20, 2021
Cigna Corporation
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-38769
(Commission File Number)
|
82-4991898
(IRS Employer
Identification No.)
|
900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area
code:
(860) 226-6000
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.01
|
CI
|
New York Stock Exchange, Inc.
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
|
On September 20, 2021, Matthew
G. Manders, President, Government & Solutions, and Timothy C. Wentworth, Chief Executive
Officer, Evernorth, notified Cigna Corporation (the “Company”) of their intention to retire, effective December 3, 2021 and
December 31, 2021, respectively. The terms of any retirement arrangement between the Company and
Mr. Manders or the Company and Mr. Wentworth will be reported on a Form 8-K as required.
On September 23, 2021, the
Company announced the appointment of Eric P. Palmer as President and Chief Executive Officer, Evernorth, effective January 1, 2022.
Mr. Palmer has served as President and Chief Operating Officer, Evernorth, since January 2021; Cigna’s Executive Vice President
and Chief Financial Officer from June 2017 until December 2020; Deputy Chief Financial Officer from February 2017 until June 2017; Senior
Vice President, Chief Business Financial Officer from November 2015 to February 2017; Vice President, Business Financial Officer, Health
Care from April 2012 to November 2015; and Vice President, Business Financial Officer, U.S. Commercial Markets from June 2010 to April
2012.
|
Item 7.01
|
Regulation FD Disclosure
|
On September 23, 2021, the
Company issued a press release announcing enterprise leadership changes.
The information in this Item
7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference
in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit
No. Description
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cigna Corporation
|
|
|
|
Date: September 23, 2021
|
By:
|
/s/
Nicole S. Jones
|
|
|
Nicole S. Jones
|
|
|
Executive Vice President and General Counsel
|
Cigna (NYSE:CI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Sep 2023 to Sep 2024